Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Edwards Lifesciences Corp’s stock clocked out at $73.36, up 0.56% from its previous closing price of $72.95. In other words, the price has increased by $0.56 from its previous closing price. On the day, 3.51 million shares were traded. EW stock price reached its highest trading level at $73.523 during the session, while it also had its lowest trading level at $72.47.
Ratios:
To gain a deeper understanding of EW’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 73.26. For the most recent quarter (mrq), Quick Ratio is recorded 3.87 and its Current Ratio is at 4.68. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On October 07, 2025, Evercore ISI Upgraded its rating to Outperform which previously was In-line but kept the price unchanged to $88.
BTIG Research Upgraded its Neutral to Buy on July 29, 2025, while the target price for the stock was maintained at $100.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 25 ’25 when Chopra Daveen sold 2,500 shares for $81.95 per share. The transaction valued at 204,865 led to the insider holds 30,996 shares of the business.
Chopra Daveen bought 2,500 shares of EW for $204,865 on Aug 25 ’25. On Aug 18 ’25, another insider, Wood Larry L, who serves as the Global President TAVR & Surg of the company, sold 8,950 shares for $78.06 each. As a result, the insider received 698,679 and left with 206,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EW now has a Market Capitalization of 43069657088 and an Enterprise Value of 39771254784. As of this moment, Edwards’s Price-to-Earnings (P/E) ratio for their current fiscal year is 50.08, and their Forward P/E ratio for the next fiscal year is 26.23. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.58 while its Price-to-Book (P/B) ratio in mrq is 4.09. Its current Enterprise Value per Revenue stands at 6.996 whereas that against EBITDA is 22.847.
Stock Price History:
The Beta on a monthly basis for EW is 1.03, which has changed by 0.07408488 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, EW has reached a high of $83.00, while it has fallen to a 52-week low of $64.89. The 50-Day Moving Average of the stock is -5.67%, while the 200-Day Moving Average is calculated to be -2.01%.
Shares Statistics:
It appears that EW traded 4.51M shares on average per day over the past three months and 4024550 shares per day over the past ten days. A total of 587.90M shares are outstanding, with a floating share count of 575.05M. Insiders hold about 2.05% of the company’s shares, while institutions hold 86.68% stake in the company. Shares short for EW as of 1759190400 were 7461785 with a Short Ratio of 1.66, compared to 1756425600 on 10351625. Therefore, it implies a Short% of Shares Outstanding of 7461785 and a Short% of Float of 1.4400001.
Earnings Estimates
A comprehensive evaluation of Edwards Lifesciences Corp (EW) is underway, with the input of 26.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.61, with high estimates of $0.7 and low estimates of $0.56.
Analysts are recommending an EPS of between $2.55 and $2.48 for the fiscal current year, implying an average EPS of $2.51. EPS for the following year is $2.79, with 31.0 analysts recommending between $2.93 and $2.66.
Revenue Estimates
In . The current quarter, 27 analysts expect revenue to total $1.5B. It ranges from a high estimate of $1.52B to a low estimate of $1.47B. As of . The current estimate, Edwards Lifesciences Corp’s year-ago sales were $1.35BFor the next quarter, 27 analysts are estimating revenue of $1.54B. There is a high estimate of $1.6B for the next quarter, whereas the lowest estimate is $1.52B.
A total of 32 analysts have provided revenue estimates for EW’s current fiscal year. The highest revenue estimate was $6.01B, while the lowest revenue estimate was $5.81B, resulting in an average revenue estimate of $5.97B. In the same quarter a year ago, actual revenue was $5.44BBased on 31 analysts’ estimates, the company’s revenue will be $6.55B in the next fiscal year. The high estimate is $6.73B and the low estimate is $6.28B.
